Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: High mortality associated with delayed treatment rather than with the degree of neutropenia

Clinical Microbiology and Infection

Volumn 22, Issue 4, 2016, Pages 352-358

  Freire, M P ^a   de Oliveira Garcia, D ^b   Garcia, C P ^a   Campagnari Bueno, M F ^b   Camargo, C H ^b   Kono Magri, A S G ^a   Francisco, G R ^b   Reghini, R ^a   Vieira, M F ^a   Ibrahim, K Y ^a   Rossi, F ^a   Hajjar, L ^a   Levin, A S ^a   Hoff, P M ^a   Pierrotti, L C ^a   Abdala, E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO ADOLFO LUTZ   (Brazil)

Author keywords

Acinetobacter baumannii; Bacterial infection; Bloodstream infection; Cancer; Carbapenem resistance; Intensive care; Mortality; Multidrug resistance; Neutropenia; Tumour infection

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; COLISTIN; GENTAMICIN; IMIPENEM; MEROPENEM; POLYMYXIN; SULTAMICILLIN; TIGECYCLINE; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ACUTE LEUKEMIA; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BLOODSTREAM INFECTION; CANCER CENTER; CANCER MORTALITY; CANCER PATIENT; CATHETER INFECTION; FEMALE; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MORTALITY RATE; MULTIPLE MYELOMA; NEUTROPENIA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPTIC SHOCK; SOLID TUMOR; ACINETOBACTER INFECTIONS; ADOLESCENT; COMPLICATION; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; NEOPLASM; RISK FACTOR; SEPSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; RETROSPECTIVE STUDIES; RISK FACTORS; SEPSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84960192859     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.12.010     Document Type: Article

References (30)

1. Bodro M., Gudiol C., Garcia-Vidal C., Tubau F., Contra A., Boix L., et al. Epidemiology, antibiotic therapy and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in cancer patients. Support Care Cancer 2014, 22:603-610.
2. Perez F., Adachi J., Bonomo R.A. Antibiotic-resistant gram-negative bacterial infections in patients with cancer. Clin Infect Dis 2014, 59:S335-S339.
3. Ruhnke M., Arnold R., Gastmeier P. Infection control issues in patients with haematological malignancies in the era of multidrug-resistant bacteria. Lancet Oncol 2014, 15:e606-e619.
4. Metana G., Demiraslan H., Kaynar L.G., Zararsiz G., Alp E., Eser B. Factors influencing the early mortality in haematological malignancy patients with nosocomial Gram negative bacilli bacteraemia: a retrospective analysis of 154 cases. Braz J Infect Dis 2013, 17:143-149.
5. Turkoglu M., Mirza E., Tunçcan O.G., Erdem G.U., Dizbay M., Yağci M., et al. Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit:risk factors and impact on mortality. J Crit Care 2011, 26:460-467.
6. Chiang M.C., Kuo S.C., Chen S.J., Yang S.P., Lee Y.T., Chen T.L. Clinical characteristics and outcomes of bacteremia due to different genomic species of Acinetobacter baumannii complex in patients with solid tumors. Infection 2012, 40:19-26.
7. Fukuta Y., Muder R.R., Agha M.E., Clarke L.G., Wagener M.M., Hensler A.M., et al. Risk factors for acquisition of multidrug-resistant Acinetobacter baumannii among cancer patients. Am J Infect Control 2013, 41:1249-1252.
8. Koprnova J., Svetlansky I., Bilikova E., Babela R., Krcmery V. Acinetobacter baumanii (AB) bacteremia in cancer patients. Support Care Cancer 2001, 9:558-559.
9. Gedik H., Simşek F., Kantürk A., Yildirmak T., Arica D., Aydin D. Bloodstream infections in patients with hematological malignancies: which is more fatal - cancer or resistant pathogens?. Ther Clin Risk Manag 2014, 10:743-752.
10. Horan C.T., Andrus M., Dudeck M.A. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008, 36:309-332.
11. Magiorakos A.P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M.E., Giske C.G., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012, 18:268-281.
12. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement 2012, CLSI, Wayne, PA.
13. European Committee on Antimicrobial Susceptibility Testing: Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0, 2014. Available at: . Accessed June 2015. http://www.eucast.org.
14. Woodford N., Ellington M.J., Coelho J.M., Turton J.F., Ward M.E., Brown S., et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 2006, 27:351-353.
15. BLAST®. (n.d.). BLAST: Basic Local Alignment Search Tool. Available at: . Retrieved 21 September 2015. http://blast.ncbi.nlm.nih.gov/Blast.cgi.
16. Seifert H., Dolzani L., Bressan R., van der Reijden T., van Strijen B., Stefanik D., et al. Standardization and interlaboratory reproducibility assessment of pulsed-field electrophoresis-generated fingerprints of Acinetobacter baumannii. J Clin Microbiol 2005, 43:4328-4335.
17. Dellinger R.P., Levy M.M., Rhodes A., Annane D., Gerlach H., Opal S.M., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41:580-637.
18. Mehta R.L., Kellum J.A., Shah S.V., Molitoris B.A., Ronco C., Warnock D.G., et al. Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007, 11:R31.
19. Cornejo-Juarez P., Vilar-Compte D., Perez-Jimenez C., Ñamendys-Silva S.A., Sandoval-Hernández S., Volkow-Fernández P. The impact of hospital acquired infections with multidrug-resistant bacterial at an oncological intensive care unit. Int J Infect Dis 2014, 31:31-34.
20. Enfield K.B., Huq N.N., Gosseling M.F., Low D.J., Hazen K.C., Toney D.M., et al. Control of simultaneous outbreaks of carbapenemase-producing enterobacteriaceae and extensively drug-resistant Acinetobacter baumannii infection in an intensive care unit using interventions promoted in the Centers for Disease Control and Prevention 2012. Infect Control Hosp Epidemiol 2014, 35:810-817.
21. Villar M., Cano M.E., Gato E., Garnacho-Montero J., Miguel Cisneros J., Ruíz de Alegría C., et al. Epidemiologic and clinical impact of Acinetobacter baumannii colonization and infection. Medicine 2014, 93:202-210.
22. Ng T.M., Teng C.B., Lye D.C., Apisarnthanarak A. A multicenter case-case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 2014, 35:49-55.
23. Vasconcelos A.T., Barth A.L., Zavascki A.P., Gales A.C., Levin A.S., Lucarevschi B.R., et al. The changing epidemiology of Acinetobacter spp producing OXA carbapenemases causing bloodstream infections in Brazil: a BrasNet report. Diagn Microbiol Infect Dis 2015, 83:382-385.
24. Freire M.P., Pierrotti L.C., Filho H.H., Ibrahim K.Y., Magri A.S., Bonazzi P.R., et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients. Eur J Clin Microbiol Infect Dis 2015, 34:277-286.
25. Huang S.T., Chiang M.C., Kuo S.C., Lee Y.T., Chiang T.H., Yang S.P., et al. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 2012, 45:356-362.
26. Chuang Y.C., Sheng W.H., Li S.Y., Lin Y.C., Wang J.T., Chen Y.C., et al. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia. Clin Infect Dis 2011, 52:352-360.
27. Batirel A., Balkan I.I., Karabay O., Agalar C., Akalin S., Alici O., et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 2014, 33:1311-1322.
28. Ni W., Shao X., Xiuzhen Di, Cui J., Wang R., Liu Y. In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents 2015, 45:8-18.
29. Zusman O., Avni T., Leibovici L., Adler A., Friberg L., Stergiopoulou T., et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother 2013, 57:5104-5111.
30. Durante-Mangoni E., Signoriello G., Andini R., Mattei A., De Cristoforo M., Murino P., et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013, 57:349-358.